Skip to content
My WebMD Sign In, Sign Up
Font Size
A
A
A

Stopping Hormone Therapy May Shorten Men's Lives

Prostate Cancer Patients on Continuous Hormone Therapy Lived Longer Than Patients Given Intermittent Treatment, Study Finds
By
WebMD Health News
Reviewed by Laura J. Martin, MD

doctor and male patient

June 4, 2012 (Chicago) -- Taking a break from hormone therapy can shorten the lives of some men with metastatic prostate cancer, researchers say.

Many men take a break from hormone therapy -- aka androgen-deprivation therapy or ADT -- to lessen its often debilitating side effects.

ADT -- which turns off production of the male hormone testosterone that fuels the growth of prostate tumors -- is a first line of treatment for metastatic disease (that has spread beyond the prostate).

But because hormone therapy blocks male hormones, it can lead to loss of sexual function and severe hot flashes. Over time, weakened bones (osteoporosis) and heart problems may develop.

But in a new study of more than 1,500 men tracked for nearly a decade, patients with minimal cancer spread given continuous ADT lived an average of about two years longer than those given intermittent (on-again, off-again) ADT.

Interrupted ADT should no longer be recommended as an initial treatment, says researcher Maha Hussain, MD, of the University of Michigan Comprehensive Cancer Center in Ann Arbor, Mich.

"Continuous therapy continues to be the standard of care," she tells WebMD.

Hussain reported the findings here at the annual meeting of the American Society of Clinical Oncology.

Intermittent ADT

Prostate cancer is the second most common cancer in men, with nearly 242,000 cases diagnosed each year in the U.S., according to the American Cancer Society. Skin cancer is the most common.

Previous smaller studies suggested that intermittent hormonal therapy -- stopping and restarting treatment periodically -- was as effective as continuous therapy, but with a lower risk of these side effects, says Bruce Roth, MD, a prostate cancer specialist at Washington University School of Medicine in St. Louis. Roth, who was not part of the study, moderated a news briefing at which the findings were presented.

As a result, interrupted ADT became widely used in the U.S., he tells WebMD.

"But this study for the first time indicates that there is a price to pay. Men need to ask themselves if they are willing to trade hot flashes for two years of their lives," he says.

Continuous ADT Beats Out Intermittent ADT

The late-stage international study involved men with hormone-sensitive cancers that had spread beyond the prostate. All were given androgen deprivation therapy with Zoladex and Casodex for seven months. Men who responded were divided into two groups, with one staying on continuous ADT and the other getting intermittent treatment. They were tracked for an average of more than nine years.

Results showed that "survival with intermittent hormone therapy was inferior to survival with continuous hormone therapy," Hussain says.

Men given continuous therapy lived an average of nearly six years, compared with about five years for men getting intermittent therapy.

Men with minimal disease spread (no cancer beyond the spine, pelvis, and lymph nodes) on continuous therapy lived an average of about seven years vs. five years for those treated intermittently -- a striking two-year difference, Hussain says.

Today on WebMD

Prostate Cancer Overview
SLIDESHOW
what is your cancer risk
HEALTH CHECK
 
Prostate Exam
VIDEO
Prostate Nerve Transplant
VIDEO
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Men Ignore
FEATURE
 
Prostate Enlarged
VIDEO
Picture Of The Prostate
ANATOMY
 
Prostate Cancer Quiz
QUIZ
screening tests for men
SLIDESHOW
 
Prostate Cancer Symptoms
VIDEO
Vitamin D
SLIDESHOW